MedPage Today on MSN
Tenecteplase unseats low-dose alteplase favored for Asian patients
Japanese trial compared lytics for bridging before endovascular thrombectomy ...
Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...
Switching from alteplase to tenecteplase as the thrombolytic used routinely for acute ischemic stroke is having multiple benefits for one US hospital system. Tenecteplase was developed as a more ...
Making the switch from alteplase to tenecteplase for stroke thrombolysis can be done successfully when the appropriate preparations are taken, and it may improve patient outcomes, the experience of a ...
Whether the evidence supports wider use of tenecteplase (TNKase; Genentech)—a thrombolytic agent with an indication for acute MI—as an alternative to alteplase (Activase; Genentech) for the treatment ...
Please provide your email address to receive an email when new articles are posted on . TNKase is the first stroke treatment approved by the FDA in almost 30 years, the manufacturer said. It is ...
Please provide your email address to receive an email when new articles are posted on . The study examined 458 adults given IV tenecteplase or placebo 4.5 to 24 hours after stroke. At 90 days after ...
The approval marks the first new stroke treatment authorized in nearly 27 years, offering an additional option for managing acute ischemic stroke in Canada. MISSISSAUGA, ON, Dec. 17, 2025 /CNW/ - ...
Tenecteplase, a genetically modified tissue plasminogen activator derived from alteplase, has recently been shown to be as effective and safe as alteplase for the treatment of acute ischemic stroke.
LOS ANGELES — Not only is tenecteplase a cheaper and more convenient thrombolytic agent than alteplase, but new research suggests it also leads to better outcomes in stroke patients selected for ...
The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults. TNKase is delivered as a single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results